High efficacy observed regardless of presence of cirrhosis, although patients with high baseline HCV RNA level were more likely to experience virologic failure.
Efficacy appeared reduced in cirrhotic patients although both groups tolerated treatment well.
12-week regimen of daclatasvir, sofosbuvir, and ribavirin associated with SVR12 rates of 83% overall in patients with advanced cirrhosis and 94% in patients with posttransplantation recurrence, high SVR rates across genotypes.
Shortening treatment duration to 8 weeks resulted in reduced rates of cure and more frequent relapse.
High efficacy observed in all patient subgroups, including hemodialysis patients.
DAA-experienced patients may also benefit from this novel regimen, although a longer treatment duration likely necessary in this population.
In the subset of study patients who have reached SVR4, extended treatment duration of 24 weeks appeared to provide greater efficacy vs 12 weeks in this difficult-to-treat population.
The SVR12 rate in this PI-experienced population was 96% overall and 95% among patients with previous virologic failure; 3 patients relapsed with treatment-emergent NS3 and NS5A RAVs.
In this phase II trial, 8-week therapy was promising, even in some cirrhotic groups, but SVR12 rates declined to below 90% when treatment duration was reduced further, dropping substantially with 4-week regimen.
Efficacy also observed in genotype 4 HCV–infected patients receiving grazoprevir/elbasvir with or without ribavirin; evaluation of efficacy in genotypes 5 and 6 require additional patient numbers.
SVR rates were consistently high in patients treated with a 16-week grazoprevir/elbasvir plus ribavirin regimen; no relapses observed in this arm.
No HCV genotype/subtype or other patient parameter was associated with a decrease in treatment efficacy for this coinfected population.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.